Thomas Brodin

Functions as a College/University

Scandinavian Life Science Invest's investment strategy aims to maximize return on investments. They are active investors in growth firms in the life science sector primarily in the areas of pharmaceutical development, biotechnology and medical technology. They generally take stakes from 10% to 49% in each firm, seeking to influence but not through a controlling interest. They invest in small and mid-sized life science firms primarily in Scandinavia and Europe. They seek long-term capital growth by constructing diversified portfolios through sector, firm size, development stage and financial status. They provide a combination of capital, industrial and financial expertise to their portfolio firms. Scandinavian Life Science Invest prefers to invest in phases after seed capital but before IPO. They look for firms with a strong patent position, clear market potential, proven medical need for the product or technology, expert science and scientific teams and incentives for key employees. The firm's exit strategies include trade sales, IPO and M&A.